Adverse Events

Boehringer Ingelheim ADA2026 BI

Biotech

ADA: Tolerability questions linger for Boehringer's obesity drug

A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.

Fraiser Kansteiner Jun 8, 2026 4:30am

ADA 2026 conference

ADA: Roche, Zealand make tolerability case for petrelintide

Jun 7, 2026 3:00am

Two aardvarks

Aardvark halts obesity trials, putting entire pipeline on pause

Mar 24, 2026 4:00am

Closeup of blue eye on black background

Kalaris pauses eye drug trial to resolve ocular inflammation

Mar 11, 2026 6:30am

Aardvark

Aardvark pauses ph. 3 hunger trial over 'cardiac observations'

Mar 2, 2026 4:40am

Make a delay and accumulation of outstanding tasks Full stop

Accent halts DHX9 inhibitor trial over adverse events

Feb 26, 2026 5:01am